Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06547970

Pharmacist Led Educational Intervention on QOL, Medication Adherence & Satisfaction on Patients With Type 1 DM

There was no previous study in Iraq to evaluate the efficacy of pharmacist-led educational intervention on patient glycemic control, quality of life and medication adherence among type 1 diabetic patients in Iraq.

Improving diabetes patients' information's about their disease control, the role of insulin and the right technique to administer it, how to deal with hyper- and hypoglycemia, about their diet and exercise.

It is important to conduct a study to evaluate the pharmacist's role in education and improving patients' quality of life.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Al-kindy Specialized center for endocrine diseases and diabetes

Baghdad, 12221, Iraq

Location status: Recruiting

Location contact

Mukdad Al Hilal, PhD

CONTACT

7712763103 ext. 00964

About this study

Aim of the Study:

The aim of the current study is to evaluate the impact of pharmacist-led educational intervention on glycemic control, quality of life and medication adherence among type 1 diabetic patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Patients age ≥ 16 years old who can speak and read the Arabic language.
  • Had been diagnosed with T1DM for at least 6 months ago.
  • Had uncontrolled hyperglycemia (glycosylated hemoglobin HbA1C ≥7% and/or fasting blood glucose >130 mg/dl)
  • Patients on the same regimen the last 3 months.
  • patients (or parents) acceptance to participate in the study.

Exclusion criteria

  • 1-Patient who have hearing, speech or cognitive deficits that would impair understanding of the questions and receiving the education.

2- Patients with comorbid conditions that may interfere with the study such as asthma, thyroid disorders, adrenal gland disorders, celiac disease, or significant renal impairment.

3-Patients who are taking corticosteroids. 4- Patients who required changing their insulin regimen, increasing the dose >20% of the previous dose. (21) 5- Patients with conditions that affect red blood cell turnover (hemolytic and other anemias, G-6-PD deficiency, recent blood transfusion, use of drugs that stimulate erythropoiesis, end stage kidney disease and pregnancy.

6-Patients unwilling to participate.

Treatment and study plan

Educational intervension

Other

an educational intervention about the disease, symptoms & how to deal with these symptoms, foot care, life style like sport and nutritional advices

Other names: follow up

Primary outcomes

  1. Glycated hemoglobin A1c (%) (HbA1c)

    Time frame: Baseline (beginning of the intervention) and the end of 3 months follow-up.

    Measurement of Glycated hemoglobin A1c (%) (HbA1c) at beginning of the intervention and the end of 3 months follow-up.

  2. The Quality of Life Scale (QoL)

    Time frame: Baseline (beginning of the intervention) and the end of 3 months follow-up.

    The score consists of four major domains including general health, social, psychological, and satisfaction issues. Ten items were selected to formulate the quality-of-life scale for Iraqi DM patients (QOLSID). The first four questions with question ten are used to directly assess satisfaction, question five is used to assess social issue while questions six and seven were used to assess emotion and stress finally question eight and nine are directly used to assess health issue. The score of each question range from 0 (poor) to 5 (optimum). Items 1,2,6 and 7 with reverse scoring. Total score = direct summation of all items scores. Total scores ≥ 32.5 points refer to good quality of life.

Secondary outcomes

  1. Anti-Diabetic Medication Adherence Scale (IADMAS)

    Time frame: Baseline (beginning of the intervention) and the end of 3 months follow-up.

    The scale consists of eight items; three items are used to directly assess medication-taking behavior by giving five responses: (1) always (daily), (2) often, (3) sometimes, (4) rarely and (5) never. The remaining five items are used to measure the determinant of non-adherence by giving a dichotomous response of "Yes" or "No". The first item aims to identify the extent of unintentional missing of medication doses; all other questions were directed to identify the extent of intentional medication non-adherence. Two items (1 and 3) were used to identify the extent of non-adherence to the time of medication taking. Four items (2, 6, 7 and 8) were formulated to identify the extent of intentional non-adherence with the prescribed medication dose. Only one item (5) aims to identify the extent of intentional non-adherence through discontinuation of taking DM medication. Scoring of all items ranged from 0 to 1, 0 for non-adherent answer and 1 for total adherence.

  2. Insulin self-administration assessment checking list

    Time frame: Baseline (beginning of the intervention) and the end of 3 months follow-up.

    The assessment form was developed based on the latest expert recommendations for best practice in insulin injection technique. to assess pharmacists' counseling and educational role about the use of insulin. Areas of assessment include Preparations for injecting insulin contain six questions, Insulin injecting technique contain nine questions, Storage and stability of insulin contain 2 questions. the answers would be yes and no

Study contacts

Contact information is provided by the study sponsor or research team.

Marwa Al Mukhtar, MSc

CONTACT

[email protected]

7901735013 ext. 00964

Sponsors and collaborators

Lead sponsor

University of Baghdad

Other

Registry information

Official study title

The Impact of Pharmacist Led Education Program on Glycemic Control, Quality of Life and Medication Adherence Among Patients With Type 1 Diabetes Mellitus

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 12, 2024
Registry last updated
Aug 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.